

BLU9931

Catalog No: tcsc4139



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

1538604-68-0

Formula:

$C_{26}H_{22}Cl_2N_4O_3$

Pathway:

Protein Tyrosine Kinase/RTK

Target:

FGFR

Purity / Grade:

>98%

Solubility:

DMSO : 17 mg/mL (33.37 mM; Need ultrasonic and warming)

Observed Molecular Weight:

509.38

Product Description


BLU9931 is a potent, selective, and irreversible **FGFR4** inhibitor with **IC₅₀** of 3 nM, about 297-, 184-, and 50-fold selectivity over

FGFR1/2/3, respectively.

IC50 & Target: IC50: 3 nM (FGFR4)

In Vitro: In MDA-MB-453 cells, BLU9931 potently inhibits phosphorylation of FGFR4 signaling pathway. BLU9931 inhibits proliferation of HCC cell lines that express an intact FGFR4 signaling complex, such as Hep 3B, HUH-7, and JHH-7 cell lines, with EC₅₀ of [1]. BLU9931 induces tumor shrinkage in hepatocellular carcinoma models that express a functioning ligand/receptor complex consisting of FGF19/FGFR4/KLB and adds to a growing list of anti-FGFR4 agents^[2].

In Vivo: BLU9931 (300 mg/kg, p.o.) leads to tumor regression and prevents this weight loss in mice bearing the FGF19-amplified Hep 3B liver tumors. In mice bearing the FGF19-overexpressing PDX-derived LIXC012 xenografts, treatment with BLU9931 (300 mg/kg, p.o.) also leads to tumor regression^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!